NAD + metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer
Journal for ImmunoTherapy of Cancer · 2024-07 · 12 (7) · e009281
DOI: 10.1136/jitc-2024-009281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 27.07.2024. Verfasst von Meihua Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cancer-Associated Fibroblasts, Nicotinamide N-Methyltransferase, Immunotherapy. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research and Development Program of China, Science and Technology Planning Project of Guangdong Province, Research and Development Program of Guangdong.
Abstract (Originalsprache)
Background
This study comprehensively investigates the association between the expression of nicotinamide N-methyltransferase (NNMT) and clinical outcomes of urothelial bladder cancer (UBC), as well as the molecular mechanisms by which NNMT in cancer-associated fibroblast (CAF) modulates tumor progression and immunotherapy resistance in UBC.
Methods
Single-cell transcriptomic analyses, immunohistochemical and immunofluorescence assays were performed on bladder cancer samples to validate the relationship between NNMT expression and clinical outcomes. A series of experiments, including chromatin immunoprecipitation assay, liquid chromatography tandem mass spectrometry assay, and CRISPR‒Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) knockout, together with in vivo models, have been established to determine the molecular functions of NNMT in CAFs in UBC.
Results
We demonstrated that elevated expression of the nicotinamide adenine dinucleotide (NAD + ) metabolism enzyme NNMT in CAFs (NNMT + CAFs) was significantly associated with non-response to programmed death-ligand 1 (PD-L1) blockade immunotherapy in patients with UBC and predicted the unfavorable prognosis of UBC in two independent large cohorts. Targeting NNMT using the inhibitor 5-Amino-1-methylquinolinium iodide significantly reduced tumor growth and enhanced the apoptotic effects of the anti-PD-L1 antibody in UBC mouse models. Mechanistically, NNMT + CAFs recruit tumor-associated macrophages via epigenetic reprogramming of serum amyloid A (SAA) to drive tumor cell proliferation and confer resistance to programmed death-1/PD-L1 blockade immunotherapy.
Conclusions
NNMT + CAFs were significantly associated with non-response to PD-L1 blockade immunotherapy in patients with UBC. Elevated NNMT, specifically in CAFs, upregulates SAA expression and enhances the recruitment and differentiation of macrophages in the tumor microenvironment, thereby directly or indirectly promoting tumor progression and conferring resistance to immunotherapies in bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P.R. China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen Universi…
- First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R.China.
- Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
- Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China.
- Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Gua…
ORCID-Profile: Meihua Yang, Bo Wang, Hao Yu, Jian Huang
Förderung
- Research and Development Program of China
- Science and Technology Planning Project of Guangdong Province
- Research and Development Program of Guangdong
- The First Affiliated Hospital of Nanchang University
- Translational Medicine of Guangzhou Bureau of Science and Information Technology
- Schools Pearl River Scholar Funded Scheme
- Guangdong Province Higher Vocational Colleges
- Key Laboratory of Malignant Tumor Molecular Mechanism
Zitieren
APA
Yang, M., Wang, B., Hou, W., Zeng, H., He, W., Zhang, X. K., Yan, D., Yu, H., Huang, L., Pei, L., Li, K., Qin, H., Lin, T., & Huang, J. (2024). NAD + metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer, 12(7), e009281. https://doi.org/10.1136/jitc-2024-009281
Vancouver
Yang M, Wang B, Hou W, Zeng H, He W, Zhang XK, et al. NAD + metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 2024;12(7):e009281. doi:10.1136/jitc-2024-009281
BibTeX
@article{Yang2024,
author = {Yang, Meihua and Wang, Bo and Hou, Weibin and Zeng, Honghui and He, Wang and Zhang, Xin-Ke and Yan, Dong and Yu, Hao and Huang, Long and Pei, Lu and Li, Kaiwen and Qin, Haide and Lin, Tianxin and Huang, Jian},
title = {NAD + metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {7},
pages = {e009281},
doi = {10.1136/jitc-2024-009281}
}
EUVIMED